Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...

They're pressing ahead with a Phase 3 trial, banking on tweaks to trial designs to tackle what they're calling a placebo ...

Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a ...

The market for non-opioid painkillers is booming in the wake of a devastating overdose crisis and an opioid industry far ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares.

While in the early stages of development, CNTX-0290 gives Lilly a backup in the non-opioid painkiller game should Pfizer-partnered tanezumab fail to be approved for marketing. The NGF inhibitor ...

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...

According to Bicon Pharma, Anapra exerts its analgesic effects by simultaneously inhibiting the glycine transporter 2 and ...